Strategic Analysis for Small-Cap Success (CING, LIPO, CARM, PMCB, OCTO)

Spotlighting five small-cap companies for the upcoming week, our focus lies on forward-looking catalysts while dissecting key entry points to evade chasing potential bottom bouncers.

Cingulate Inc. (NASDAQ: CING) - Cingulate Inc.'s stock closed last week at $1.34, a decrease of under 1%. The company recently completed a public offering, issuing a total of 3,750,000 shares of common stock, Series A warrants, and Series B warrants at a price of $2.00 per share. In December, they received FDA guidance on advancing their investigational asset CTx-2103 for anxiety treatment, with plans to file an IND application in the first half of 2024. CEO Shane J. Schaffer expressed optimism about the potential for approval under the 505(b)(2) pathway, which could streamline the process. With increased trading volume last week, we're closely monitoring the $1.51 resistance level while awaiting further updates from the company.

--

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) - Lipella Pharmaceuticals Inc.'s stock closed last week's trading session up nearly 1% at $1.05. In December, the company marked its first anniversary as a publicly traded entity. Headquartered in Pittsburgh, PA, Lipella has achieved significant progress over the past year, reaching key milestones and advancing its pipeline with three clinical indications and two orphan drug designations. Notably, the company successfully concluded a Type C meeting with the FDA regarding its leading drug candidate, LP-10, for the treatment of hemorrhagic cystitis (HC). CEO Jonathan Kaufman expressed satisfaction with the meeting's outcome, emphasizing the FDA's clear guidance for the company's Phase-2b trial for LP-10. Additionally, Lipella's LP-310 has received orphan drug designation for the treatment of oral graft-versus-host disease (GVHD) with tacrolimus. The company plans to submit a Phase 2a IND for this indication in Q1 2024. We'll be monitoring for company updates and watching for a potential resistance break at $1.25.

--

Carisma Therapeutics, Inc. (NASDAQ: CARM) - Carisma Therapeutics, Inc.'s stock closed last week's trading session up nearly 1% at $2.59. Additionally, the company announced that Steven Kelly, President and CEO, will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6th at 2:50 pm ET. In November, Carisma received FDA clearance for its Investigational New Drug application (IND) for CT-0525, a gene-modified autologous cellular therapy for treating solid tumors overexpressing HER2. With the FDA's Study May Proceed notification, Carisma anticipates initiating a Phase 1 study in the coming months, targeting the treatment of the first patient in the first half of 2024. As we await further updates from the company, we'll be monitoring for a potential resistance break at $2.80.

--

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) - PharmaCyte Biotech, Inc.'s shares concluded last week's trading session with a slight dip of under 1% to $2.08. At the end of October, the company issued an update on its investigation of its Cell-in-a-Box technology and outlined initial next steps in development. After a thorough scientific review of accumulated data, the company is currently in the process of arranging a meeting with the U.S. Food and Drug Administration (FDA) to seek guidance on advancing the technology further. This meeting is anticipated to take place in the first quarter of 2024. Dr. Michael M.I. Abecassis, a Board member of PharmaCyte and Professor of Surgery and Microbiology, as well as the Dean of the College of Medicine – Tucson at the University of Arizona, expressed, "We believe that discussions with the Food and Drug Administration regarding Cell-in-a-Box should provide a path forward as we continue to explore other promising local delivery technologies that may offer similar benefits for patients grappling with this challenging and life-threatening clinical issue." While awaiting further updates from the company, attention is directed towards a possible resistance break of $2.35.

--

Eightco Holdings Inc. (NASDAQ: OCTO) - Eightco Holdings Inc.'s shares closed last week's trading session at $0.65, marking a modest increase of just over 1%. In the previous month, the company announced an early completion of its final repayment under the Prepayment and Redemption Agreement with Hudson Bay Master Fund Ltd., pertaining to the Senior Secured Convertible Note issued in March 2023. With the successful repayment of the Hudson Bay Note, the company not only reduces its debt levels but also enhances its capacity to attract efficient capital for the growth of its subsidiary, Forever 8 Fund, LLC. Furthermore, Eightco Holdings conducted a private placement, adhering to Nasdaq rules, priced at $0.82 per share, along with issuing promissory notes to certain investors. Concurrently, efforts are underway to streamline ongoing costs at the parent company level, enabling a sharper focus on driving growth through its primary subsidiary, Forever 8. As we await forthcoming updates from the company, attention is drawn towards a potential resistance break around the $0.72 mark.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.